Humoral and T-cell–mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients
Open Access
- 17 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (4)
Abstract
Background: SARS-CoV-2 vaccination induces a varied immune response among persons with chronic liver disease (CLD) and solid organ transplant recipients (SOTRs). We aimed to evaluate the humoral and T-cell–mediated immune responses to SARS-CoV-2 vaccination in these groups. Methods: Blood samples were collected following the completion of a standard SARS-CoV-2 vaccination (2 doses of either BNT162b2 or mRNA-12732), and a subset of patients had a blood sample collected after a single mRNA booster vaccine. Three separate methods were utilized to determine immune responses, including an anti-spike protein antibody titer, neutralizing antibody capacity, and T-cell–mediated immunity. Results: The cohort included 24 patients with chronic liver disease, 27 SOTRs, and 9 controls. Patients with chronic liver disease had similar immune responses to the wild-type SARS-CoV-2 compared with controls following a standard vaccine regimen and single booster vaccine. SOTRs had significantly lower anti-S1 protein antibodies (p < 0.001), neutralizing capacity (p < 0.001), and T-cell–mediated immunity response (p = 0.021) to the wild-type SARS-CoV-2 compared with controls following a standard vaccine regimen. Following a single booster vaccine, immune responses across groups were not significantly different but numerically lower in SOTRs. The neutralization capacity of the B.1.1.529 Omicron variant was not significantly different between groups after a standard vaccine regimen (p = 0.87) and was significantly lower in the SOTR group when compared with controls after a single booster vaccine (p = 0.048). Conclusion: The immunogenicity of the SARS-CoV-2 vaccine is complex and multifactorial. Ongoing and longitudinal evaluation of SARS-CoV-2 humoral and cellular responses is valuable and necessary to allow frequent re-evaluation of these patient populations.Keywords
This publication has 25 references indexed in Scilit:
- SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant PatientsClinical Gastroenterology and Hepatology, 2022
- Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?Liver Transplantation, 2021
- Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseasesJournal of Hepatology, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsNew England Journal of Medicine, 2021
- SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipientsScience Immunology, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipientsJournal of Hepatology, 2021
- American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver DiseaseHepatology, 2021
- Characterization of hepatitis E-specific cell-mediated immune response using IFN-γ ELISPOT assayJournal of Immunological Methods, 2007